Moderna Just Made mRNA Exciting Again

Modernaβs stock recently surged after the company and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine, combined with Keytruda, in high...
Discuss precision therapy, disease targeting, biomarkers, and off-target risk.

Modernaβs stock recently surged after the company and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine, combined with Keytruda, in high...